N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

Rotator Cuff Tendon Repair With FiberLocker System Patch Augmentation

Sponsor: ZuriMED Technologies AG • ClinicalTrials.gov ID: NCT07005063

Registry updated: 2026-09-01
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The overall objective of this clinical investigation is to assess the safety and efficacy of full-thickness arthroscopic rotator cuff repairs augmented with the FiberLocker System for the subjects. The primary outcome of the investigation is to assess the safety after full-thickness arthroscopic rotator cuff repairs augmented with the FiberLocker System in terms of postoperative adverse events through the 12-month follow-up. Main secondary outcomes include measures of efficacy and clinical performance evaluated at 6-week, 4.5-month, and 12-month follow-ups including retear rate assessed using MRI and different functional performance scores.

Interventions

  • FiberLocker® System (encompassing SpeedPatch® PET and FiberLocker Instrument® SN) (Device)
    The FiberLocker® System is a mechanical augmentation system that includes an implant (SpeedPatch® PET) and an instrument (FiberLocker® Instrument SN) for its attachment. The implant is composed of non-woven PET fibers, and the instrument features a reciprocating needle at its tip, which pushes the individual patch fibers into the underlying tendon tissue

Eligibility criteria

Inclusion Criteria: 1. Subject requires surgical treatment of a full-thickness rotator cuff tear, according to Balgrist standard procedure 2. Full-thickness tear of the supraspinatus or combined infraspinatus and supraspinatus 3. The rotator cuff tear is of traumatic origin. 4. Subject is ≥ 40 years of age \& ≤ 65 years of age. 5. Primary rotator cuff repair 6. Informed Consent signed by the subject 7. Pre-operative MRI performed Exclusion Criteria: 1. Vulnerable subjects (as defined in ISO 14155) 2. Subjects who do not have the power of judgement or are unable to fully understand all aspects of the investigation that are relevant to the decision to participate 3. Participation in another investigation with an investigational drug or another MD within the 30 days preceding and during the present investigation, 4. Previous enrolment into the current investigation, 5. Enrolment of the PI, his/her family members, employees and other dependent persons, 6. Inability to follow the procedures of the investigation, or known or suspected non-compliance, e.g. due to language problems, psychological disorders, dementia, drug or alcohol abuse, etc. of the subject 7. Active smoker 8. History of claustrophobia that would prevent an MRI of the index shoulder 9. Presence of an implanted metallic device or other implants that would contraindicate acquisition or inhibit radiologist review of an MRI of the index shoulder 10. Pregnant or planning to become pregnant during the study period 11. Breast feeding women 12. Subject has conditions or circumstances that would interfere with study requirements. 13. Contraindications and limitations of the MD as described in the IFUs. 14. Partial rotator cuff tears 15. History or known allergy or intolerance to polyester 16. Complete full-thickness subscapularis tears greater than the superior 1/3 of the tendon, with Lafosse grade 3 or greater 17. Massive rotator cuff tears, tear size equal to or greater than 4 cm in the anterior-posterior dimension or irreparable rotator cuff tear 18. Limited space or exposure for implant delivery 19. Structural or pathological condition of the bone or soft tissue that could impair healing. 20. Intraoperative rotator cuff tear characteristics differ from preoperatively expected characteristics and fulfil one of the abovementioned criteria 21. Fatty infiltration of the index shoulder rotator cuff muscle \> Goutallier Score 2 22. Corticosteroid injection in the operative shoulder within 6 weeks of operation 23. Subject shows frozen shoulder/adhesive capsulitis at day of surgery 24. Cases of moderate to severe osteoarthritis 25. Patients with inflammatory disease or auto-immune based joint diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, arthropathy) 26. Subjects with diabetes type I or II 27. The subject currently has an acute infection in the area surrounding the surgical site 28. Evidence of active infection, osteomyelitis, sepsis or distant infection which could spread to the index joint. 29. Any comorbidity or condition that renders the patient a poor surgical candidate as determined by the Investigator.

Conditions

Rotator Cuff Tear Rotator Cuff Injury Rotator Cuff Rupture

Locations

  • Balgrist University Hospital — Zurich, Canton of Zurich, Switzerland
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record